NewAmsterdam Pharma Company N.V. (NAMS)
$20.19-4.99%Close
SELLCRISIS · day 6
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.4B
- Beta
- 0.10
- P/E (TTM)
- -9.26
- Short % float
- 23.60%
- Days to cover
- 9.4
- SI change
- +21.6%
- 1W
- -9.34%
- 1M
- -9.70%
- vs SPY 1W
- -9.20%
- vs SPY 1M
- -12.21%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on NAMS?
- LOPJLB’s latest quantitative signal on NewAmsterdam Pharma Company N.V. (NAMS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is NAMS in?
- NewAmsterdam Pharma Company N.V. (NAMS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does NewAmsterdam Pharma Company N.V. (NAMS) do?
- NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular dise…